This study aimed to establish the safety and effectiveness of renal denervation using the new multielectrode device (EnligHTN) that allows simultaneous ablation of the entire renal artery. 39 patients with resistant hypertension to multiple drugs were included. Procedure was successfully performed in all patients, and no serious adverse events were observed. At 6 months, a reduction in ambulatory blood pressure of 25 mmHg for systolic and 7 mmHg for diastolic was observed. The Ambulatory blood pressure monitoring (ABPM) reduction was 8 mmHg for systolic and 2 mmHg for diastolic.
Conclusion:
No serious adverse events related to the procedure or device with a sustained reduction in blood pressure at 6 months were observed.
Stephen Worthley
2014-05-23
Title: 6-month results of first-in-man sympathetic renal artery denervation using a next generation multi-electrode renal artery denervation system in patients with drug-resistant hypertension
